12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Antiretroviral treatment (ART) has been massively scaled up to decrease human immunodeficiency virus (HIV)–related morbidity, mortality, and HIV transmission. However, despite documented increases in ART coverage, morbidity and mortality have remained substantial. This study describes trends in the numbers and characteristics of patients with very advanced HIV disease in the Western Cape, South Africa.

          Methods

          Annual cross-sectional snapshots of CD4 distributions were described over 10 years, derived from a province-wide cohort of all HIV patients receiving CD4 cell count testing in the public sector. Patients with a first CD4 count <50 cells/µL in each year were characterized with respect to prior CD4 and viral load testing, ART access, and retention in ART care.

          Results

          Patients attending HIV care for the first time initially constituted the largest group of those with CD4 count <50 cells/µL, dropping proportionally over the decade from 60.9% to 26.7%. By contrast, the proportion who were ART experienced increased from 14.3% to 56.7%. In patients with CD4 counts <50 cells/µL in 2016, 51.8% were ART experienced, of whom 76% could be confirmed to be off ART or had recent viremia. More than half who were ART experienced with a CD4 count <50 cells/µL in 2016 were men, compared to approximately one-third of all patients on ART in the same year.

          Conclusions

          Ongoing HIV-associated morbidity now results largely from treatment-experienced patients not being in continuous care or not being fully virologically suppressed. Innovative interventions to retain ART patients in effective care are an essential priority for the ongoing HIV response.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Rates of HIV testing and diagnosis in South Africa: successes and challenges.

          UNAIDS aims for 90% of HIV-positive individuals to be diagnosed by 2020, but few attempts have been made in developing countries to estimate the fraction of the HIV-positive population that has been diagnosed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study

            Retention in care is an essential component of meeting the UNAIDS "90-90-90" HIV treatment targets. In Khayelitsha township (population ~500,000) in Cape Town, South Africa, more than 50,000 patients have received antiretroviral therapy (ART) since the inception of this public-sector program in 2001. Disengagement from care remains an important challenge. We sought to determine the incidence of and risk factors associated with disengagement from care during 2013-2014 and outcomes for those who disengaged.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up

              Abstract The public sector scale-up of antiretroviral therapy (ART) in South Africa commenced in 2004. We aimed to describe the hospital-level disease burden and factors contributing to morbidity and mortality among hospitalized HIV-positive patients in the era of widespread ART availability. Between June 2012 and October 2013, unselected patients admitted to medical wards at a public sector district hospital in Cape Town were enrolled in this cross-sectional study with prospective follow-up. HIV testing was systematically offered and HIV-infected patients were systematically screened for TB. The spectrum of admission diagnoses among HIV-positive patients was documented, vital status at 90 and 180 days ascertained and factors independently associated with death determined. Among 1018 medical admissions, HIV status was ascertained in 99.5%: 60.1% (n = 609) were HIV-positive and 96.1% (n = 585) were enrolled. Of these, 84.4% were aware of their HIV-positive status before admission. ART status was naive in 35.7%, current in 45.0%, and interrupted in 19.3%. The most frequent primary clinical diagnoses were newly diagnosed TB (n = 196, 33.5%), other bacterial infection (n = 100, 17.1%), and acquired immunodeficiency syndrome (AIDS)-defining illnesses other than TB (n = 64, 10.9%). By 90 days follow-up, 175 (29.9%) required readmission and 78 (13.3%) died. Commonest causes of death were TB (37.2%) and other AIDS-defining illnesses (24.4%). Independent predictors of mortality were AIDS-defining illnesses other than TB, low hemoglobin, and impaired renal function. HIV still accounts for nearly two-thirds of medical admissions in this South African hospital and is associated with high mortality. Strategies to improve linkage to care, ART adherence/retention and TB prevention are key to reducing HIV-related hospitalizations in this setting.
                Bookmark

                Author and article information

                Journal
                Clin Infect Dis
                Clin. Infect. Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                01 April 2018
                04 March 2018
                04 March 2018
                : 66
                : Suppl 2 , Advanced HIV Disease
                : S118-S125
                Affiliations
                [1 ]Centre for Infectious Diseases, Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town
                [2 ]Médecins Sans Frontières, Southern African Medical Unit, Cape Town, South Africa
                [3 ]HIV Department, World Health Organization, Geneva
                [4 ]Department of Health, Provincial Government of the Western Cape
                [5 ]Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town
                [6 ]Department of Medicine, University of Cape Town and Groote Schuur Hospital
                [7 ]Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, National Health Laboratory Service
                [8 ]Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
                Author notes
                Correspondence: M. Osler, University of Cape Town, Anzio Road, Falmouth Bldg, Rm 5.35, Observatory, Cape Town 7925, South Africa ( meg.osler@ 123456uct.ac.za ).
                Article
                cix1140
                10.1093/cid/cix1140
                5850025
                29514233
                2b4fbd68-4154-45af-a2ca-081031dbb8e8
                © 2018 World Health Organization; licensee Oxford University Press USA.

                This is an open access article distributed under the terms of the Creative Commons Attribution IGO License ( http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organisation or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.

                History
                Page count
                Pages: 8
                Funding
                Funded by: Wellcome Trust 10.13039/100004440
                Award ID: 098316
                Funded by: South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa
                Award ID: 64787
                Funded by: NRF incentive funding
                Award ID: 85858
                Funded by: National Institutes of Health 10.13039/100000002
                Award ID: R01 HD080465
                Award ID: U01 AI069924
                Award ID: R01 MH106600
                Funded by: Bill and Melinda Gates Foundation 10.13039/100000865
                Award ID: OPP1164272
                Categories
                Advanced HIV Disease

                Infectious disease & Microbiology
                antiretroviral therapy,cd4 count,morbidity,advanced hiv disease,south africa

                Comments

                Comment on this article